MYC along with stemness-associated markers CD44 and SOX2 are positively regulated upon ligand–independent EPHA2 (erythropoietin-producing hepatocellular A2) activation, which strongly increases stemness and chemoresistance in SCLC [178]. This evidence concerns the gene EPHA2 and small cell lung carcinoma.